Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3)

This grant will support efforts to optimize and evaluate pharmacodynamic (PD) measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The objectives of the grant will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic development.

Funding: no fixed limit 

Duration: UG3- up to 3 years; UH3- 3 years. Total should NOT exceed 5 years

Research Authority due date: 10 days prior to submission 

LOI (encouraged) due dates: 21.9.22, 21.1.23, 21.5.23, 21.9.23, 21.1.24, 21.5.24, 21.9.24, 21.1.25, 20.5.25

Full proposal due dates: 21.10.22, 21.2.23, 21.6.23, 21.10.23, 21.2.24, 21.6.24, 21.10.24, 21.2.25, 20.6.25